Polyphor AG

After a busy 2023 on the business development front, Basilea Pharmaceutica Ltd. has started the year by adding more assets to its pipeline with the acquisition of a preclinical antibiotics program f

Since it has become difficult for many biopharmaceutical companies to raise money during the past year and a half, several firms have been forced to cut costs to make remaining cash balances last long

Spexis AG , the Swiss biotech that was only created at the end of last year through the merger of troubled Polyphor AG and EnBiotix , is already facing an uncertain future as it battles for funds t

Struggling Swiss biotech Polyphor AG , which has suffered a string of setbacks in the clinic, has been handed a lifeline by negotiating a merger with EnBiotix, Inc. of the US, a privately held rare